Literature DB >> 15885642

PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis.

Hanlu Ding1, Xiongfei Wu, Wenda Gao.   

Abstract

T cell activation is affected by both stimulatory and inhibitory co-signaling. MHC class II-expressing renal tubular epithelial cells (TEC) can function as APC for T cells. To study the influence of inhibitory ligands on TEC-mediated T cell activation, we examined the expression of programmed death ligand-1 (PD-L1) on human TEC line HK-2 cells, as well as in normal and diseased kidney samples. RT-PCR, FACS, and immunocytochemistry showed that PD-L1 is constitutively expressed on HK-2 cells, and is dramatically upregulated by IFN-gamma. In situ hybridization and immunohistochemical staining revealed constitutive low expression of PD-L1 on proximal tubules at both mRNA and protein levels in normal kidneys, but much higher expression in kidneys with type IV lupus nephritis. In vitro, pretreatment of IFN-gamma-stimulated HK-2 cells with anti-PD-L1 significantly enhanced IL-2 secretion from cocultured, mitogen-activated Jurkat or human peripheral blood T cells. These results suggest that the PD-L1:PD-1 pathway negatively regulates T cell activation by TEC, and may play an inhibitory role in TEC-mediated immune activation and immunopathology in the kidney.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885642     DOI: 10.1016/j.clim.2005.01.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  38 in total

Review 1.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

Review 2.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

3.  Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted.

Authors:  Jeremy S Tilstra; Lyndsay Avery; Ashley V Menk; Rachael A Gordon; Shuchi Smita; Lawrence P Kane; Maria Chikina; Greg M Delgoffe; Mark J Shlomchik
Journal:  J Clin Invest       Date:  2018-09-24       Impact factor: 14.808

4.  Both PD-1 ligands protect the kidney from ischemia reperfusion injury.

Authors:  Katarzyna Jaworska; Joanna Ratajczak; Liping Huang; Kristen Whalen; Mana Yang; Brian K Stevens; Gilbert R Kinsey
Journal:  J Immunol       Date:  2014-11-17       Impact factor: 5.422

Review 5.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

Review 6.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

7.  Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy.

Authors:  M Xipell; I Victoria; V Hoffmann; J Villarreal; A García-Herrera; O Reig; L Rodas; M Blasco; E Poch; B Mellado; L F Quintana
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

8.  PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.

Authors:  Wanhua Yang; Peter W Chen; Haochuan Li; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02-22       Impact factor: 4.799

Review 9.  PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.

Authors:  Christopher D Nishimura; Marc C Pulanco; Wei Cui; Liming Lu; Xingxing Zang
Journal:  Trends Mol Med       Date:  2020-11-13       Impact factor: 11.951

10.  Tubular cell HIV-entry through apoptosed CD4 T cells: a novel pathway.

Authors:  Priyanka Singh; Hersh Goel; Mohammad Husain; Xiqian Lan; Joanna Mikulak; Ashwani Malthotra; Saul Teichberg; Helena Schmidtmayerova; Pravin C Singhal
Journal:  Virology       Date:  2012-10-03       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.